Alam Ridwan, Rezaee Michael E, Pallauf Maximilian, Elias Roy, Yerrapragada Anirudh, Enikeev Dmitry, Fang Dong, Shariat Shahrokh F, Woldu Solomon L, Ged Yasser M A, Singla Nirmish
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria.
Urol Oncol. 2023 Nov;41(11):460.e1-460.e9. doi: 10.1016/j.urolonc.2023.08.016. Epub 2023 Sep 14.
Racially driven outcomes in cancer are challenging to study. Studies evaluating the impact of race in renal cell carcinoma (RCC) outcomes are inconsistent and unable to disentangle socioeconomic disparities from inherent biological differences. We therefore seek to investigate socioeconomic determinants of racial disparities with respect to overall survival (OS) when comparing Black and White patients with RCC.
We queried the National Cancer Database (NCDB) for patients diagnosed with RCC between 2004 and 2017 with complete clinicodemographic data. Patients were examined across various stages (all, cT1aN0M0, and cM1) and subtypes (all, clear cell, or papillary). We performed Cox proportional hazards regression with adjustment for socioeconomic and disease factors.
There were 386,589 patients with RCC, of whom 46,507 (12.0%) were Black. Black patients were generally younger, had more comorbid conditions, less likely to be insured, in a lower income quartile, had lower rates of high school completion, were more likely to have papillary RCC histology, and more likely to be diagnosed at a lower stage of RCC than their white counterparts. By stage, Black patients demonstrated a 16% (any stage), 22.5% (small renal mass [SRM]), and 15% (metastatic) higher risk of mortality than White patients. Survival differences were also evident in histology-specific subanalyses. Socioeconomic factors played a larger role in predicting OS among patients with SRMs than in patients with metastasis.
Black patients with RCC demonstrate worse survival outcomes compared to White patients across all stages. Socioeconomic disparities between races play a significant role in influencing survival in RCC.
研究种族因素对癌症治疗结果的影响具有挑战性。评估种族因素对肾细胞癌(RCC)治疗结果影响的研究结果并不一致,且无法区分社会经济差异与内在生物学差异。因此,我们试图在比较黑人和白人RCC患者时,研究种族差异在总生存期(OS)方面的社会经济决定因素。
我们查询了国家癌症数据库(NCDB)中2004年至2017年间诊断为RCC且具有完整临床人口统计学数据的患者。对不同分期(所有分期、cT1aN0M0和cM1)和亚型(所有亚型、透明细胞或乳头状)的患者进行了检查。我们进行了Cox比例风险回归分析,并对社会经济和疾病因素进行了调整。
共有386,589例RCC患者,其中46,507例(12.0%)为黑人。黑人患者通常更年轻,合并症更多,保险覆盖率更低,收入处于较低四分位数,高中完成率较低,乳头状RCC组织学的发生率更高,且比白人患者更有可能在RCC较低分期时被诊断出来。按分期来看,黑人患者的死亡风险比白人患者高16%(任何分期)、22.5%(小肾肿块[SRM])和15%(转移性)。在组织学特异性亚分析中,生存差异也很明显。社会经济因素在预测SRM患者的OS方面比在转移性患者中发挥了更大的作用。
与白人患者相比,各分期的黑人RCC患者的生存结果更差。种族之间的社会经济差异在影响RCC患者生存方面起着重要作用。